RU2010152689A - Способы лечения с применением белков, связывающих рецептор интерлейкина-21 - Google Patents

Способы лечения с применением белков, связывающих рецептор интерлейкина-21 Download PDF

Info

Publication number
RU2010152689A
RU2010152689A RU2010152689/15A RU2010152689A RU2010152689A RU 2010152689 A RU2010152689 A RU 2010152689A RU 2010152689/15 A RU2010152689/15 A RU 2010152689/15A RU 2010152689 A RU2010152689 A RU 2010152689A RU 2010152689 A RU2010152689 A RU 2010152689A
Authority
RU
Russia
Prior art keywords
binding protein
binding fragment
individual
group
antigen
Prior art date
Application number
RU2010152689/15A
Other languages
English (en)
Russian (ru)
Inventor
Лэйрд БЛУМ (US)
Лэйрд БЛУМ
Давиндер ДЖИЛЛ (US)
Давиндер ДЖИЛЛ
Юлия ВУГМЕЙСТЕР (US)
Юлия ВУГМЕЙСТЕР
Дебора А. ЯНГ (US)
Дебора А. Янг
Маргот О'ТУЛ (US)
Маргот О'ТУЛ
Хит М. ГЬЮЭЙ (US)
Хит М. ГЬЮЭЙ
Карисса К. ЭДКИНС (US)
Карисса К. ЭДКИНС
Эми Арлин УИВЕР (US)
Эми Арлин УИВЕР
Садхана ДЖАИН (US)
Садхана ДЖАИН
Майя АРАИ (US)
Майя АРАИ
Original Assignee
УАЙТ ЭлЭлСи (US)
УАЙТ ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by УАЙТ ЭлЭлСи (US), УАЙТ ЭлЭлСи filed Critical УАЙТ ЭлЭлСи (US)
Publication of RU2010152689A publication Critical patent/RU2010152689A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
RU2010152689/15A 2008-05-23 2009-05-26 Способы лечения с применением белков, связывающих рецептор интерлейкина-21 RU2010152689A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5554308P 2008-05-23 2008-05-23
US61/055,543 2008-05-23
US9947608P 2008-09-23 2008-09-23
US61/099,476 2008-09-23

Publications (1)

Publication Number Publication Date
RU2010152689A true RU2010152689A (ru) 2012-06-27

Family

ID=41092124

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010152689/15A RU2010152689A (ru) 2008-05-23 2009-05-26 Способы лечения с применением белков, связывающих рецептор интерлейкина-21

Country Status (13)

Country Link
US (2) US8178097B2 (enExample)
EP (1) EP2296689A1 (enExample)
JP (1) JP2011520989A (enExample)
KR (1) KR20110021919A (enExample)
CN (1) CN102149403A (enExample)
AR (1) AR072136A1 (enExample)
AU (1) AU2009248812A1 (enExample)
BR (1) BRPI0912998A2 (enExample)
CA (1) CA2725154A1 (enExample)
IL (1) IL209455A0 (enExample)
MX (1) MX2010012812A (enExample)
RU (1) RU2010152689A (enExample)
WO (1) WO2009143526A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
KR20130011056A (ko) * 2011-07-20 2013-01-30 주식회사에이앤알쎄라퓨틱스 염증표적 수용체 및 염증 질환 치료용 약물 운반체
CN102532320A (zh) * 2012-03-06 2012-07-04 中国药科大学 全人源的抗人白介素21受体的单链抗体及其应用
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
WO2019160978A1 (en) * 2018-02-13 2019-08-22 Cedars-Sinai Medical Center Methods and systems for identification and treatment of pathological neurodegeneration and age-related cognitive decline
KR102255964B1 (ko) * 2018-11-19 2021-05-24 한국생명공학연구원 신규한 il-15-il-21 융합 폴리펩티드 및 이의 용도
PH12022550211A1 (en) * 2019-08-02 2022-12-12 Cttq Akeso Shanghai Biomed Tech Co Ltd Anti-pd-1 antibody and medical use thereof
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6576744B1 (en) 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
CN102406937A (zh) 1999-03-09 2012-04-11 津莫吉尼蒂克斯公司 新的细胞因子zalpha11配体
AU5142300A (en) 1999-05-18 2000-12-05 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
AU2001253127A1 (en) 2000-04-05 2001-10-23 Zymogenetics Inc. Soluble zalpha11 cytokine receptors
AU2001263088B2 (en) 2000-05-11 2006-07-20 Genetics Institute, Llc. Mu-1, member of the cytokine receptor family
DE60233888D1 (de) 2001-11-05 2009-11-12 Zymogenetics Inc Il-21-antagonisten
US20040016010A1 (en) 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
PT1531850E (pt) 2002-06-07 2012-05-07 Zymogenetics Inc Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos
KR20050037552A (ko) 2002-07-15 2005-04-22 와이어쓰 Ｔ 헬퍼(ｔｈ) 세포 발생 및 기능을 조절하는 방법 및조성물
JP4914209B2 (ja) 2003-03-14 2012-04-11 ワイス ヒトｉｌ−２１受容体に対する抗体および該抗体の使用
MXPA05010035A (es) * 2003-03-21 2005-11-17 Wyeth Corp Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
US7276478B2 (en) 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
BRPI0510996A (pt) 2004-05-19 2007-12-04 Wyeth Corp métodos para melhorar um sintoma de um distúrbio atópico, e para tratar ou prevenir um distúrbio atópico em um paciente, métodos para modular a produção de igg e ige em uma célula, e nìveis relativos de ige e igg, composição farmacêutica, recipiente, métodos para avaliar um paciente tendo ou suspeito de ter um distúrbio atópico, e para avaliar um paciente quanto ao risco de um distúrbio atópico
US20060039902A1 (en) * 2004-08-05 2006-02-23 Young Deborah A Antagonizing interleukin-21 receptor activity
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Also Published As

Publication number Publication date
JP2011520989A (ja) 2011-07-21
IL209455A0 (en) 2011-01-31
CN102149403A (zh) 2011-08-10
US20120276102A1 (en) 2012-11-01
WO2009143526A1 (en) 2009-11-26
EP2296689A1 (en) 2011-03-23
MX2010012812A (es) 2011-01-21
KR20110021919A (ko) 2011-03-04
BRPI0912998A2 (pt) 2015-10-13
CA2725154A1 (en) 2009-11-26
US20090298081A1 (en) 2009-12-03
AR072136A1 (es) 2010-08-11
US8178097B2 (en) 2012-05-15
AU2009248812A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
RU2010152689A (ru) Способы лечения с применением белков, связывающих рецептор интерлейкина-21
Locci et al. Activin A programs the differentiation of human TFH cells
Corvaisier et al. IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation
Zhang et al. Augmentation of circulating follicular helper T cells and their impact on autoreactive B cells in myasthenia gravis
Mahmood et al. CD27-IgD-memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis
Vebr et al. A narrative review of cytokine networks: pathophysiological and therapeutic implications for inflammatory bowel disease pathogenesis
Lee et al. Regulating human Th17 cells via differential expression of IL-1 receptor
Zhou et al. Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease
Hardt et al. Integrated single cell and spatial transcriptomics reveal autoreactive differentiated B cells in joints of early rheumatoid arthritis
Coffre et al. Combinatorial control of Th17 and Th1 cell functions by genetic variations in genes associated with the interleukin‐23 signaling pathway in spondyloarthritis
Moghaddas et al. The classification, genetic diagnosis and modelling of monogenic autoinflammatory disorders
JP6868655B2 (ja) Ｃｄ６結合パートナーの使用およびそれに基づく方法
Blum et al. Circulating plasmablasts are elevated and produce pathogenic anti‐endothelial cell autoantibodies in idiopathic pulmonary arterial hypertension
Fineschi et al. Inflammation and interferon signatures in peripheral B-lymphocytes and sera of individuals with fibromyalgia
Chetaille Nézondet et al. The evaluation of cytokines to help establish diagnosis and guide treatment of autoinflammatory and autoimmune diseases
Ridgley et al. Il-6 mediated transcriptional programming of naïve CD4+ T cells in early rheumatoid arthritis drives dysregulated effector function
Aira et al. Immunological evaluation of rheumatoid arthritis patients treated with itolizumab
US20190094223A1 (en) Infiltrating immune cell proportions predict anti-tnf response in colon biopsies
Davies et al. Aberrant cell signalling in PBMCs upon IFN‐α stimulation in primary Sjögren's syndrome patients associates with type I interferon signature
Lu et al. Single-cell transcriptome analysis and protein profiling reveal broad immune system activation in IgG4-related disease
Byng-Maddick et al. Tumor necrosis factor (TNF) bioactivity at the site of an acute cell-mediated immune response is preserved in rheumatoid arthritis patients responding to anti-TNF therapy
Wines et al. Distinctive expression of interleukin‐23 receptor subunits on human Th17 and γδ T cells
Akatani et al. Interleukin-6 signaling blockade induces regulatory plasmablasts in neuromyelitis optica spectrum disorder
Rakebrandt et al. Innate acting memory Th1 cells modulate heterologous diseases
Cohen et al. Transplantation elicits a clonally diverse CD8+ T cell response that is comprised of potent CD43+ effectors

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20140506